EP1599482A1 - Derives de pyrazolo 1,5-a]pyrimidine - Google Patents
Derives de pyrazolo 1,5-a]pyrimidineInfo
- Publication number
- EP1599482A1 EP1599482A1 EP04716064A EP04716064A EP1599482A1 EP 1599482 A1 EP1599482 A1 EP 1599482A1 EP 04716064 A EP04716064 A EP 04716064A EP 04716064 A EP04716064 A EP 04716064A EP 1599482 A1 EP1599482 A1 EP 1599482A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- compound
- hydrogen
- alkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- R 1 , R 2 and R 4 are not all H.
- R 1 - R 4 are as defined in claim 1;
- R 1 is hydrogen
- R 2 is hydrogen, -CN, -SCH 3 , -NH 2 , -COOH or COCF 3
- R 3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH 3 , -OEt, -COOH);
- R 4 is hydrogen or -CH 3 ;
- R 5 is
- Ar 1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.
- R60 is benzyl or ?-MeO-benzyl
- n is 1, 2 or 3.
- autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma, Sjogren's syndrome, juvenile rheumatoid arthritis, psoriatic arthritis, chronic thyroiditis, Graves 's disease, autoimmune gastritis, diabetes, autoimmune haemolytis anaemia, autoimmune neutropaenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.
- a method of treating or preventing a protein kinase-mediated disorder in an individual comprises administering to said individual a compound as claimed in any one of (1), (3) to (38) or a composition as defined in (77) or (78).
- autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.
- An assay for determining the activity of the compounds as defined in any one of (1), (3) to (38), comprising providing a system for assaying the activity and assaying the activity of a compound as defined in any one of (1), (3) to (38).
- a method of inhibiting the activity or function of a protein kinase comprises exposing a protein kinase to a compound as defined in any one of (1), (3) to (38) or a composition as defined in (77) or (78).
- R 0 which may be the same or different, are as d ⁇ efined for R S ;
- R 9 °° and -i R 7Q together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclylalkynyl;
- alkyl relates to both straight chain or branched alkyl radicals of 1 to 8 carbon atoms including, but not limited to, methyl, ethyl, ra-propyl, isopropyl, r ⁇ -butyl, see-butyl, isobutyl, tert-butyl, ra-pentyl, isopentyl, neopentyl, tert-pentyl, 2-methylpentyl, 4-methylpentyl, 1-ethylbutyl, n-hexyl, n-heptyl, 2-methylhexyl, 5-methylhexyl, 1,1-dimethyl ⁇ entyl, 6-methylheptyl and rc-octyl.
- cycloalkyl means a cycloalkyl radical of 3 to 8 carbon atoms including but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- alkenyl means a straight chain, branched or ring structured alkenyl radical of 2 to 8 carbon atoms and containing one or more carbon-carbon double bonds and includes, but is not limited to, vinyl, allyl, isopropenyl, 1-propenyl, 2-butenyl, 1-bulenyl, 2-methyl-l-propenyl, 2-methyl-3-pentenyl, 1-pentenyl, 2-pentenyl, 4-melhyl-l-pentenyl, 1-hexenyl, 2-hexenyl, 2-cyclopenlenyl, 2-cyclohexenyl, 2-heptenyl, 2-octenyl, 3-cyclopentenyl, 1,3-butadienyl and 1,5-hexadienyl. When they have cis and trans geometrical isomers, both isomers are included.
- alkynyl means a straight chain or branched alkynyl radical of 2 to 8 carbon atoms and containing one or more carbon-carbon triple bonds and includes, but is not limited to, ethynyl, 2-propynyl, 1-propynyl, 1-butynyl, 2-butynyl, 3-hexynyl, 3-methyl-l-butynyl, 3,3-dimethyl-l-butynyl, 3-pentynyl, 2-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, l-methyl-3-pentynyl, l-methyl-3-hexynyl, 2-heptynyl and 2-octynyl.
- Heteroaryl means an aromatic 5-10 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S and containing one ring or being fused to one or more saturated or unsaturated rings.
- heteroaryl include, but are not limited to, monovalent group including furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, thiadiazole, oxadiazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, benzofuran, dibenzofuran, benzothiophene, indole, benzimidazole, benzothiazole, benzoxazole, quinoline, isoquinoline, quinazoline, quinoxaline, purine, pteridine, phenoxazine and phenozine.
- Heterocyclyl means a 3-10 membered ring system containing 1 to 4 heteroatoms selected from N, O or S.
- Heterocyclylalkyl is a group comprising a combination of the heterocyclyl and the alkyl. Examples thereof include, but are not limited to, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 3-furilmethyl, 2-(3-indolyl)ethyl, 2-morpholinoethyl, 2-piperidinoethyl, 2-(4-pyridyl)-ethyl, 3-(l-piperadinyl)-propyl, 3-(2-thienyl)-propyl, and 2-(l-imidazole)ethyl.
- Heterocyclylalkenyl used herein is a group comprising a combination of the heterocyclyl and the alkenyl. Examples thereof include, but are not limited to, (3- ⁇ yridyl)vinyl, 3-(3-thienyl)propene-2-yl, 3-(4-morpholinyl)-l-propenyl and 4-(l- ⁇ iperidyl)-2-butenyl. When they have cis and trans geometrical isomers, both isomers are included.
- Arylalkynyl used herein is a group comprising a combination of the aryl and the alkynyl. Examples thereof include, but are not limited to, phenylethynyl and 4-phenyl-2-butynyl.
- Heterocyclylalkynyl used herein is a group comprising a combination of the heterocyclyl and the alkynyl. Examples thereof include, but are not limited to, 4-(4-pyridyl)-2-butynyl and 5-(l-piperazinyl)-2-pentynyl.
- Halogen means F, Cl, Br or I.
- C2-C8 alkynyl means C2-C8 alkynyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO 2 , -CHO, heterocyclyl,
- C3-C8 cycloalkyl means C3-C8 cycloalkyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO 2 , -CHO, heterocyclyl,
- C6-C14 aryl means C6-C14 aryl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO , -CHO, heterocyclyl,
- optionally substituted heterocyclyl means heterocyclyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO 2 , -CHO, heterocyclyl,
- R is substituted phenyl
- R 4 is preferably selected from hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl. More preferably R 4 is hydrogen, methyl or ethyl.
- R is preferably selected from C3-C8 substituted cycloalkyl
- R 5 is preferably selected from cyclohexyl
- substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl -OH and -NH 2 ], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl
- substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl -OH and -NH 2 ].
- R 6 is preferably selected from hydrogen and C1-C8 optionally substituted alkyl. More preferably R 6 is hydrogen.
- R is hydrogen
- R is C6-C14 aryl group substituted by C6-C14 optionally substituted aryl or optionally substituted heterocyclyl
- C6-C14 aryl group as R 3 may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO , C1-C8 optionally substituted alkyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl), -NR 17 R 18 (R 17 and R 18 , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R 4 is C1-C8 optionally substituted alkyl, R 5 is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ], unsubstit
- R is hydrogen, R is hydrogen, R is C6-C14 aryl group substituted by -G-R 15 ⁇ G is -(CO)-; R 15 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) or -NR 17 R 18 (R 17 and R 18 , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) ⁇ [wherein C6-C14 aryl group as R 3 may be substituted by one or more substituents selected from the group
- R 1 is hydrogen
- R 2 is hydrogen
- R 3 is unsubstituted bicyclic heteroaryl or substituted bicyclic heteroaryl
- substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO2, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR R (R and R , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NH(CO)R 19 (R 19 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocycl
- R 1 is hydrogen
- R 2 is F
- R 3 is C6-C14 aryl group substituted by C6-C14 optionally substituted aryl or optionally substituted heterocyclyl
- C6-C14 aryl group as R 3 may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO 2 , C1-C8 optionally substituted alkyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl), -NR 17 R 18 (R 17 and R 18 , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)],
- R 4 is hydrogen
- R 5 is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ], unsubstituted saturated heterocycly
- R 1 is hydrogen
- R 2 is F
- R 3 is C6-C14 aryl group substituted by -OR 16
- R 16 is C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl
- C6-C14 aryl group as R 3 may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO 2 , C1-C8 optionally substituted alkyl, -OR 16 (R 16 is hydrogen, C1-C8
- R 1 is hydrogen, R 2 is F, R 3 is C6-C14 aryl group substituted by -G-R 15 ⁇ G is -(CO)-; R 15 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) or -NR 17 R 18
- R and R which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) ⁇ [wherein C6-C14 aryl group as R may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO , C1-C8 optionally substituted alkyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl), -Mi 17 R 18 (R 17 and E.
- R 18 which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)]
- R is hydrogen
- R s is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ] and R6 is hydrogen.
- R is hydrogen, R is F, R is unsubstituted bicyclic heteroaryl or substituted bicyclic heteroaryl
- As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO 2 , C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR 16 (R 16 is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR 17 R 18 (R 17 and R 18 , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NH(CO)R 19 (R 19 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted
- R 1 is hydrogen
- R 2 is halogen, -CN or -SCH 3
- P 3 is C6-C14 optionally substituted aryl, optionally substituted bicyclic heteroaryl
- P 4 is hydrogen
- R 5 is cyclohexyl
- substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ]
- R6 is hydrogen.
- R 1 is hydrogen
- R 2 is halogen or -CN
- R 3 is C6-C14 optionally substituted aryl, optionally substituted bicyclic heteroaryl
- R is C1-C8 optionally substituted alkyl
- R 5 is cyclohexyl
- substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH 2 ]
- As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH ]
- R6 is hydrogen.
- the compounds of the first aspect may be provided as a salt, preferably as a pharmaceutically acceptable salt of the compounds of formula I.
- pharmaceutically acceptable salts of these compounds include those derived from organic acids such as acetic acid, malic acid, lartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulphonic acid, benzenesulphonic acid, trifluoroacetic acid and ?-toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, p-toluenesulphonate, liydrocliloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases.
- Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; N-methylglucosamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like.
- amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; N-methylglucosamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzy
- Salts may be prepared in a conventional manner using methods well known in the art. Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid. Where a compound of the invention contains an acidic function, a base salt of said compound may be prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution e.g. by evaporation. The compounds of this invention may also exist in solvated or hydrated forms.
- the invention also extends to a prodrug of the aforementioned compounds such as an ester or amide thereof.
- a prodrug is any compound that may be converted under physiological conditions or by solvolysis to any of the compounds of the invention or to a pharmaceutically acceptable salt of the compounds of the invention.
- a rodrug may be inactive when administered lo a subject but is converted in vivo to an active compound of the invention.
- R 1 - R 6 are as defined for formula I above;
- R 45 is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl; with the provisos: that R 1 , R 2 and R 4 are not all H;
- R 1 - R 6 are as defined for formula I above;
- R 45 is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl; with the provisos: that R 1 , R 2 and R 4 are not all H;
- R 45 is preferably tert-butyl or benzyl.
- the present invention provides a process for the manufacture of a compound of the invention by reaction of a compound of formula II, III, IN, V, VI, N ⁇ , v-oi. iN-oi, ⁇ -oi, ⁇ -03, ⁇ -04, ⁇ -06, 11-08, 11-13, ⁇ -15, 11-18, 11-20, ⁇ -22, ⁇ -24,
- halogenating agent e.g. N-chlorosuccinimide, N-bromosuccinimide (for example as described in J. Med. Chem. 1976, 19, 517.) or iodine monochloride
- R is methyl or ethyl
- oxidizing agent e.g. iodosobenzene diacetate for Hofmann rearrangement in the presence of benzyl alcohol (for example as described in J. Org. Chem. 1979, 44, 1746 and Synthesis 1981, 266. ), followed by removal of the benzyloxy carbonyl group by hydrogenolysis in the presence of palladium on carbon (for example as described in Protective Groups in Organic Synthesis, 3rd Ed, John Wiley & Sons Inc) 17) reacting a compound of the formula 11-08
- Ar 1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl
- alkyl halide e. g. methyl iodide in the presence of base, followed by trifluoroacetic acid and sodium hydroxide, respectively, for removal of t-butoxycarbonyl and trifluoroacetyl group from a compound 24) reacting a compound of the formula 11-08
- alkyl halide e. g. methyl iodide in the presence of base e. g. sodium hydride 26
- R 60 is benzyl or 7-MeO-benzyl; n is 1, 2 or 3 27) reacting a compound of the formula 1-28
- a compound of formula I may undergo one or more further reactions to provide a different compound of formula I.
- a compound may undergo a reduction, oxidation, elimination, substitution and/or addition reaction.
- Figure 2 - 8 shows a general reaction scheme for the preparation of compounds of Formula I.
- the compounds of formula V, VI, VII and VIII are either known or can be prepared by methods analogous to those known for preparing analogous known compounds.
- the present invention provides a composition comprising a compound of the invention in combination with a pharmaceutically acceptable carrier, diluent or excipient.
- composition may also comprise one or more additional active agents, such as an anti-inflammatory agent (for example a p38 inhibitor, glutamate receptor antagonist, or a calcium channel antagonist), a chemotherapeulic agent and/or an antiproliferative agent.
- an anti-inflammatory agent for example a p38 inhibitor, glutamate receptor antagonist, or a calcium channel antagonist
- a chemotherapeulic agent for example a p38 inhibitor, glutamate receptor antagonist, or a calcium channel antagonist
- an antiproliferative agent for example a p38 inhibitor, glutamate receptor antagonist, or a calcium channel antagonist
- Suitable carriers and/or diluents are well known in the art and include pharmaceutical grade starch, mannitol, lactose, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, (or other sugar), magnesium carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably sterile).
- the composition may be a mixed preparation of a composition or may be a combined preparation for simultaneous, separate or sequential use (including administration).
- composition can be formulated as liquids or solids, for example solutions, syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable aqueous or non-aqueous liquid carrier(s) for example water, ethanol, glycerine, polyethylene glycol or an oil.
- a suitable aqueous or non-aqueous liquid carrier(s) for example water, ethanol, glycerine, polyethylene glycol or an oil.
- the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
- suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and microcrystalline cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- powders, granules or pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- compositions for oral administration may be designed to protect the active ingredient against degradation as it passes through the alimentary tract, for example by an outer coating of the formulation on a tablet or capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous or non-aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous or non-aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- compositions for nasal or oral administration may conveniently be formulated as aerosols, drops, gels and powders.
- Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
- the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
- the dosage form comprises an aerosol dispenser, it will contain a pharmaceutically acceptable propellant.
- the aerosol dosage forms can also take the form of a pump-atomiser.
- compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
- a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
- compositions for rectal or vaginal administration are conveniently in the form of suppositories (containing a conventional suppository base such as cocoa butter), pessaries, vaginal tabs, foams or enemas.
- Compositions suitable for transdermal administration include ointments, gels, patches and injections including powder injections.
- composition is in unit dose form such as a tablet, capsule or ampoule.
- the present invention provides a process for the manufacture of a composition according of the invention which comprises admixing one or more compounds of the invention with one more pharmaceutically acceptable excipients, carriers or diluents.
- the manufacture can be carried out by standard techniques well known in the art and involves combining a compound according to the first aspect of the invention and the pharmaceutically acceptable carrier or diluent.
- the composition may be in any form including a tablet, a liquid, a capsule, and a powder or in the form of a food product, e.g. a functional food. In the latter case the food product itself may act as the pharmaceutically acceptable carrier.
- the present invention provides a compound or composition of the invention, for use in medicine.
- this aspect provides a compound of the first aspect, or a composition of the third aspect of the present invention, for the prevention or treatment of a protein kinase-mediated disorder.
- the compounds of the first aspect of the invention may thus be used for the inhibition of protein kinase.
- a t5 protein kinase-mediated disorder is any disease or deleterious condition in which protein kinase plays a role.
- Examples include neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and thrombin induced platelet aggregation.
- the compounds of the present invention are particularly useful for the prevention or treatment of a neurodegenerative disorder.
- the neurodegenerative disorder results from apoptosis and/or inflammation.
- Examples of neurodegenerative disorders are: dementia; Alzheimer's disease; Parkinson's disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea; Sydenham's chorea; hypoglycemia; head and spinal cord trauma including traumatic head injury; acute and chronic pain; epilepsy and seizures; olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIN-infected patient.
- the compounds of the invention can also be used to prevent or treat disorders resulting from inflammation. These include, for example, inflammatory bowel disorder, bronchitis, asthma, acute pancreatitis, chronic pancreatitis, allergies of various types, and possibly Alzheimer's disease.
- Autoimmune diseases which may also be treated or prevented by the compounds of the present invention include rheumatoid arthritis, systemic lupus erythematosus, Sj ⁇ gren syndrome, psoriatic arthritis, glomerulonephritis, scleroderma, chronic thyroiditis, Graves 's disease, autoimmune gastritis, diabetes, autoimmune haemolylis anaemia, autoimmune neutropaenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.
- a compound of the present invention may be administered simultaneously, subsequently or sequentially with one or more other active agent, such as an anti-inflammatory agent e.g. p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent.
- an anti-inflammatory agent e.g. p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent.
- a p38 inhibitor may be administered to a patient prior to administering a compound of the present invention.
- the compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 2000 mg, preferably between 30 mg and 1000 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula I, or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy, for example for a week or more.
- the present invention provides a method of treating or preventing a protein kinase-mediated disorder in an individual, which method comprises administering lo said individual one or more compounds of the invention or a composition of the invention.
- the active compound is preferably administered in a cumulative effective amount.
- the individual may be in need of the treatment or prevention. Any of the protein kinase-mediated disorders listed above in relation to the fifth aspect may be the subject of treatment or pre /ention according lo the sixth aspect.
- One or more other active agent may be administered to the individual simultaneously, subsequently or sequentially to administering the compound.
- the other active agent may be an anti-inflammatory agent such as a p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent.
- the present invention provides an assay for determining the activity of the compounds of the present invention, comprising providing a system for assaying the activity and assaying the activity of the compound.
- the assay is for the protein kinase inhibiting activity of the compound.
- the compounds of the invention may be assayed in vitro, in vivo, in silico, or in a primary cell culture or a cell line. In vitro assays include assays that determine inhibition of the kinase activity of activated protein kinase.
- in vitro assays may quantitale the ability of a compound to bind protein kinase and may be measured either by radiolabelling the compound prior to binding, then isolating the inhibitor/ protein kinase complex and determining the amount of the radiolabel bound or by running a competition experiment where new inhibitors are incubated with protein kinase bound to known radioligands.
- An example of an assay which may be used is Scintillation Proximity Assay (SPA), preferably using radiolabelled ATP.
- ELISA Enzymerase kinase may be used in these assays.
- the present invention provides a method of inhibiting the activity or function of a protein kinase, which method comprises exposing a protein kinase to a compound or a composition of the invention.
- the method may be performed in a research model, in vitro, in silico, or in vivo such as in an animal model.
- a suitable animal model may be a kainic acid model in rat or mice, traumatic brain injury model in rat, or MPTP in mice for neurodegenerative disorder and a collagen induced arthritis model in rat or mice, type II collagen-antibodies induced arthritis in mice, or a LPS induced endotoxin shock model in mice for inflammatory disease.
- solvent B 10% solvent A: 90% 1-13 min
- solvent B 10% ⁇ 70% solvent A: 90% ⁇ 30% 13-14 min
- solvent B 70% ⁇ 100% solvent A: 30% — > 0% 14-16 min
- solvent B 100% solvent A: 0% 16-19 min
- solvent B 100% — > 10% solvent A: 0% -> 90%
- Solvent: A: H20/acelonilrile 95/5
- Methyl magnesium chloride (0.25 mL, 3M solution) was added cautiously to a solution of
- Tris(dibenzylideneacetone)dipalladium (0) (2 mol %), 2,2'-bis(diphenylphosphino)-l,l'-binaphtyl (4 mol %) and sodium tert-butoxide (1.2 equivalents) were added sequentially under an atmosphere of nitrogen.
- the reaction was heated and agitated overnight at 80 °C following which the reaction was filtered through a 0.45 micron filter. The solvent was removed in vacuo and the residue was resuspended in CH 2 C1 2 (0.2 mL). Trifluoroacetic acid (0.8 mL) was added and the reactions allowed to stand for 1 h at room temperature.
- triphenyl phosphine (362 mg, 1.38 mmol) were added triphenyl phosphine(362 mg, 1.38 mmol), a solution of diethyl azodicarboxylate in toluene (0.6 mL, 1.38 mmol; 40% solution) and DPPA
- the kinase reaction was conducted in a round-bottomed polypropylene 96-well plate.
- MAPKAP-Kinase 2 was diluted to 0.5 mU/ L in diluent buffer (50 mM Tris/HCl. pH7.5, 0.1 mM EGTA, 0.1% (v/v) ⁇ -mercaptoethanol, 1 mg/mL BSA).
- the activity is presented as +, ++, or +++ representing active, more active and very active based on assays conducted at typically 1 - 100 ⁇ M).
- CDK-1 was diluted to 0.5 U/ L in diluent buffer (50 mM Tris/HCl. pH7.5, 0.1 mM EGTA, 0.1% (v/v) ⁇ -mercaptoethanol, 1 mg/mL BSA).
- CDK-1 Compounds that inhibit CDK-1 (IC 50 ⁇ 100 ⁇ M) are; 2, 7, 9, 10, 11, 12, 14, 15, 16, 17,
- CDK-2 Assay a) The kinase reaction was conducted in a round-bottomed polypropylene 96-well plate. CDK-2 was diluted to 0.5 ng/ L in diluent buffer (50 mM Tris/HCl. pH7.5, 0.1 mM EGTA, 0.1% (v/v) ⁇ -mercaptoethanol, 1 mg ml BSA).
- reaction was initiated by further addition of 20 ⁇ L of a CDK2 enzyme solution [2.5 mU recombinant human CDK2/cyclin A, 50 mM Tris buffer (pH 7.5), 0.1 mM EGTA, 0.1 % ⁇ -mercaptoethanol, 0.1% BSA].
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0304665A GB0304665D0 (en) | 2003-02-28 | 2003-02-28 | Compounds |
GB0304665 | 2003-02-28 | ||
US50069503P | 2003-09-08 | 2003-09-08 | |
US500695P | 2003-09-08 | ||
GB0329446 | 2003-12-19 | ||
GB0329446A GB0329446D0 (en) | 2003-12-19 | 2003-12-19 | Compounds |
PCT/JP2004/002522 WO2004076458A1 (fr) | 2003-02-28 | 2004-03-01 | Derives de pyrazolo[1,5-a]pyrimidine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1599482A1 true EP1599482A1 (fr) | 2005-11-30 |
EP1599482A4 EP1599482A4 (fr) | 2008-10-01 |
Family
ID=32931047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04716064A Withdrawn EP1599482A4 (fr) | 2003-02-28 | 2004-03-01 | Derives de pyrazolo 1,5-a pyrimidine |
Country Status (12)
Country | Link |
---|---|
US (1) | US7557110B2 (fr) |
EP (1) | EP1599482A4 (fr) |
JP (1) | JP4564485B2 (fr) |
KR (1) | KR20050115252A (fr) |
AU (1) | AU2004215481B2 (fr) |
BR (1) | BRPI0407834A (fr) |
CA (1) | CA2516824A1 (fr) |
CO (1) | CO5650257A2 (fr) |
MA (1) | MA27711A1 (fr) |
MX (1) | MXPA05008955A (fr) |
NO (1) | NO20053955L (fr) |
WO (1) | WO2004076458A1 (fr) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20070270408A1 (en) * | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
US20070027156A1 (en) * | 2003-09-09 | 2007-02-01 | Hisao Nakai | Crf antagonists and heterobicyclic compounds |
EP1671962A1 (fr) * | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Nouveau compose heterocyclique fondu et utilisation correspondante |
DE10357565A1 (de) * | 2003-12-10 | 2005-07-07 | Bayer Cropscience Ag | Pyrazolopyrimidine |
DE102004008807A1 (de) * | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
WO2006033796A1 (fr) * | 2004-09-17 | 2006-03-30 | Wyeth | Pyrazolo [1,5-a] pyrimidines substituees et leur procede de fabrication |
EP1802623A1 (fr) * | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | Composes spiro actifs du type a- hydroxysteroide deshydrogenase de type 1 |
CA2591125A1 (fr) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Antagonistes de recepteur a2a de pyrazolo [1,5-a]pyrimidine adenosine |
DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
JPWO2006098519A1 (ja) * | 2005-03-17 | 2008-08-28 | 帝人ファーマ株式会社 | ピラゾロピリミジン誘導体またはその医学上許容される塩 |
US7473694B2 (en) | 2005-03-17 | 2009-01-06 | Teijin Pharma Limited | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof |
US7417053B2 (en) | 2005-04-07 | 2008-08-26 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
WO2007017678A1 (fr) * | 2005-08-09 | 2007-02-15 | Eirx Therapeutics Limited | Composes de pyrazolo[1,5-a] pyrimidine et leurs compositions pharmaceutiques |
EP1926734A1 (fr) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Composes de pyrazolopyridine et de pyrazolopyrimidine utilises comme modulateurs d'enzymes kinases |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CN101312977B (zh) * | 2005-09-22 | 2012-06-13 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶调节剂的稠合杂环化合物 |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2007044441A2 (fr) * | 2005-10-06 | 2007-04-19 | Schering Corporation | Methodes destinees a inhiber des proteines kinases |
EP1945207A2 (fr) * | 2005-11-01 | 2008-07-23 | Transtech Pharma, Inc. | Utilisation pharmaceutique des amides substitués |
JP2009514818A (ja) * | 2005-11-01 | 2009-04-09 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換アミドの製薬学的用途 |
US20100168083A1 (en) * | 2006-03-21 | 2010-07-01 | Soren Ebdrup | Adamantane derivatives for the treatment of the metabolic syndrome |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
BRPI0710669A2 (pt) | 2006-04-07 | 2011-08-16 | High Point Pharmaceuticals Llc | compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1 |
EP1878721A1 (fr) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides en tant qu'inhibiteurs de la 11-beta-hydroxysteroid dehydrogenase type 1 |
US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1900739A1 (fr) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Dérivés de diazolodiazine comme inhibiteurs de kinases |
JP5274805B2 (ja) * | 2006-09-20 | 2013-08-28 | 三菱化学株式会社 | フッ素化芳香族化合物の製造方法 |
EP1918291A1 (fr) * | 2006-10-30 | 2008-05-07 | Novartis AG | Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase |
WO2008101885A1 (fr) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | Nouveaux composés |
AU2008219326B2 (en) * | 2007-02-23 | 2012-12-13 | Vtv Therapeutics Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
EP2125704A1 (fr) * | 2007-02-23 | 2009-12-02 | High Point Pharmaceuticals, LLC | N-adamantyl benzamides utilisés en tant qu'inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase |
WO2008101907A2 (fr) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | Nouveaux composés |
CA2679866A1 (fr) * | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- et benzimidazole amides comme inhibiteurs des hydroxysteroide deshydrogenases |
JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
US20100137377A1 (en) * | 2007-04-11 | 2010-06-03 | Soren Ebdrup Et Al | Novel compounds |
CA2685036A1 (fr) * | 2007-04-24 | 2008-11-06 | High Point Pharmaceuticals, Llc | Utilisation pharmaceutique d'amides substitues |
ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
MX2010001462A (es) | 2007-08-27 | 2010-03-01 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados. |
CA2706946A1 (fr) * | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a] pyrimidines en tant qu'inhibiteurs de proteine kinase |
WO2009100375A1 (fr) * | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Imidazopyridazines substituées utiles en tant qu’inhibiteurs de kinase |
JP5432982B2 (ja) * | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ1阻害剤 |
EP2271645A1 (fr) * | 2008-04-07 | 2011-01-12 | Irm Llc | Composés et compositions en tant qu inhibiteurs de kinase |
CN102223798A (zh) * | 2008-09-24 | 2011-10-19 | 巴斯夫欧洲公司 | 用于防治无脊椎动物害虫的吡唑化合物 |
CN104211688B (zh) | 2008-09-24 | 2016-04-13 | 巴斯夫欧洲公司 | 防治无脊椎动物害虫的吡唑化合物 |
JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
WO2011003793A1 (fr) | 2009-07-06 | 2011-01-13 | Basf Se | Composés pyridazine destinés à la lutte contre les nuisibles invertébrés |
WO2011003796A1 (fr) | 2009-07-06 | 2011-01-13 | Basf Se | Composés pyridazine destinés à la lutte contre les nuisibles invertébrés |
BR112012001597A2 (pt) | 2009-07-24 | 2015-09-01 | Basf Se | Método para controlar e/ou combater pestes de invertebrados, método para a proteção do material de propagação de planta e/ou das plantas que crescem do mesmo, material de propagação de planta e método para tratar ou proteger um animal de infestação ou infecção por parasitas |
CA2782684C (fr) * | 2009-12-04 | 2018-09-04 | Mustapha Haddach | Pyrazolopyrimidines et heterocycles associes en tant qu'inhibiteurs de ck2 |
EP2519517B1 (fr) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase raf de type ii |
WO2012178125A1 (fr) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Composés inhibiteurs de la kinase atr |
EP2734520B1 (fr) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
EP2822935B1 (fr) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase c-jun-terminale (jnk) |
WO2013144532A1 (fr) * | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | Dérivés de pyrimidine 3-cyano-5-arylamino -7-cycloalkylaminopyrrolo [1, 5-a] et leurs utilisations comme agents antitumoraux |
WO2014063061A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine |
PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
EP2970288A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
EP2970289A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Composés utiles en tant qu'inhibiteurs de la kinase atr |
WO2014143240A1 (fr) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
EP3057956B1 (fr) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7) |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
JP6543252B2 (ja) | 2013-12-06 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体 |
GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
SG11201608242XA (en) | 2014-04-04 | 2016-10-28 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP3129371B1 (fr) * | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibiteurs de kinase cycline-dépendante 7 (cdk7) |
MX2016015874A (es) | 2014-06-05 | 2017-03-27 | Vertex Pharma | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
WO2016105528A2 (fr) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2016201370A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
EP4019515A1 (fr) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
CA3000684A1 (fr) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
AU2017319500C1 (en) | 2016-08-31 | 2022-10-20 | Les Laboratoires Servier | Inhibitors of cellular metabolic processes |
JP7216705B2 (ja) * | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用方法 |
FI3661935T3 (fi) * | 2017-08-11 | 2023-01-13 | Kinaasin estäjinä käyttökelpoiset pyratsolipyrimidiinit | |
GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
EP3849981B1 (fr) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Dérivés de pyrazolo[1,5-a]pyrimidine-3-carboxamide utiles dans le traitement du psoriasis et du lupus érythémateux disséminé |
AU2019360941A1 (en) * | 2018-10-15 | 2021-04-29 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
US20220135567A1 (en) * | 2019-02-07 | 2022-05-05 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
CN113874021A (zh) | 2019-03-26 | 2021-12-31 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
TW202128698A (zh) | 2019-11-08 | 2021-08-01 | 美商凡帝克斯生物科學公司 | Tyk2假激酶配位體 |
EP4103279B1 (fr) | 2020-02-12 | 2024-05-01 | Eli Lilly and Company | Dérivés de 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide substitués |
AR121251A1 (es) | 2020-02-12 | 2022-05-04 | Lilly Co Eli | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
CN115925712A (zh) * | 2022-12-09 | 2023-04-07 | 南京友怡医药科技有限公司 | 一种靶向抗肿瘤药物化合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077954A2 (fr) * | 2004-02-11 | 2005-08-25 | Schering Corporation | Nouvelles pyrazolopyrimidines tenant lieu d'inhibiteurs de la kinase dependant de la cycline |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100191774B1 (ko) | 1991-04-22 | 1999-06-15 | 오스카 아끼히꼬 | 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제 |
US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
EP0628559B1 (fr) * | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Composés de pyrimidine et leur application comme agents pharmaceutiques |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CA2483306A1 (fr) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive |
DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
MXPA05002570A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
KR101088922B1 (ko) * | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
CA2497544C (fr) * | 2002-09-04 | 2010-11-02 | Schering Corporation | Nouveaux pyrazolopyrimidines en tant qu'inhibiteurs de la kinase dependantes des cyclines |
TW200413377A (en) | 2002-09-04 | 2004-08-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
-
2004
- 2004-03-01 CA CA002516824A patent/CA2516824A1/fr not_active Abandoned
- 2004-03-01 US US10/547,080 patent/US7557110B2/en not_active Expired - Fee Related
- 2004-03-01 JP JP2006502687A patent/JP4564485B2/ja not_active Expired - Fee Related
- 2004-03-01 BR BRPI0407834-9A patent/BRPI0407834A/pt not_active IP Right Cessation
- 2004-03-01 AU AU2004215481A patent/AU2004215481B2/en not_active Expired - Fee Related
- 2004-03-01 KR KR1020057015871A patent/KR20050115252A/ko not_active Application Discontinuation
- 2004-03-01 MX MXPA05008955A patent/MXPA05008955A/es unknown
- 2004-03-01 EP EP04716064A patent/EP1599482A4/fr not_active Withdrawn
- 2004-03-01 WO PCT/JP2004/002522 patent/WO2004076458A1/fr active Application Filing
-
2005
- 2005-08-12 MA MA28441A patent/MA27711A1/fr unknown
- 2005-08-25 NO NO20053955A patent/NO20053955L/no not_active Application Discontinuation
- 2005-08-26 CO CO05085412A patent/CO5650257A2/es not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077954A2 (fr) * | 2004-02-11 | 2005-08-25 | Schering Corporation | Nouvelles pyrazolopyrimidines tenant lieu d'inhibiteurs de la kinase dependant de la cycline |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004076458A1 * |
Also Published As
Publication number | Publication date |
---|---|
MA27711A1 (fr) | 2006-01-02 |
CO5650257A2 (es) | 2006-06-30 |
CA2516824A1 (fr) | 2004-09-10 |
WO2004076458A1 (fr) | 2004-09-10 |
KR20050115252A (ko) | 2005-12-07 |
MXPA05008955A (es) | 2006-02-22 |
JP4564485B2 (ja) | 2010-10-20 |
NO20053955D0 (no) | 2005-08-25 |
NO20053955L (no) | 2005-09-22 |
EP1599482A4 (fr) | 2008-10-01 |
AU2004215481A1 (en) | 2004-09-10 |
AU2004215481B2 (en) | 2010-11-11 |
US20060189632A1 (en) | 2006-08-24 |
US7557110B2 (en) | 2009-07-07 |
BRPI0407834A (pt) | 2006-02-14 |
JP2006519226A (ja) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004076458A1 (fr) | Derives de pyrazolo[1,5-a]pyrimidine | |
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
CN104910161B (zh) | 作为jak抑制剂的吡唑并嘧啶化合物和方法 | |
EP1608651A1 (fr) | Inhibiteurs de proteine kinase | |
EP3157925B1 (fr) | Dérivés d'imidazopyridazine en tant qu'inhibiteurs de caséine kinase 1 delta/epsilon | |
EA021504B1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a | |
KR100868841B1 (ko) | 치환된2-피리디닐-6,7,8,9-테트라히드로피리미도[1,2-a]피리미딘-4-온 및7-피리디닐-2,3-디히드로이미다조[1,2-a]피리미딘-5(1h)온유도체 | |
CN100482665C (zh) | 吡唑并[1,5-a]嘧啶衍生物 | |
EP2935272B1 (fr) | Pyrazole imidazopyrazines substitues par pyrazole comme inhibiteurs de casein kinase 1 d/e | |
TWI762534B (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
WO2017088723A1 (fr) | Triazolopipérazine substituée inhibiteur de parp, procédé de préparation correspondant, et son utilisation | |
CA2602303A1 (fr) | Derives d'azole tricycliques, leur fabrication et leur utilisation en tant que principes pharmaceutiques | |
AU2017373758A1 (en) | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | |
CA2576949A1 (fr) | Derives de la pyrazolo[1,5-a]pyrimidine | |
WO2021099837A1 (fr) | Composés antagonistes du récepteur de l'adénosine | |
KR102130253B1 (ko) | 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염 | |
CN113166148B (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
KR101746199B1 (ko) | 질소 함유 헤테로아릴 유도체 및 GSK3β 저해제로서의 이의 용도 | |
CA2631034A1 (fr) | Derives tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques | |
CN115073468B (zh) | 咪唑并吡嗪类btk抑制剂的制备及用途 | |
US20060135514A1 (en) | Pyrazolo[1,5-a]pyrimidine derivatives | |
WO2015145369A1 (fr) | Procédé pour la préparation de composés d'imidazo[4,5-c]quinoline substitués, d'intermédiaires et de polymorphes de ceux-ci | |
Ohashi | Discovery of Novel Hedgehog Signaling Inhibitor | |
大橋知洋 | Discovery of Novel Hedgehog Signaling Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050906 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RAX | Requested extension states of the european patent have changed |
Extension state: LT Payment date: 20050906 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1084664 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LE, JOELLE,C/O BIO FOCUS Inventor name: HARRIS, CLIFFORD JOHN,C/O BIO FOCUS Inventor name: SIMPSON, DONALD JAMES,C/O BIO FOCUS Inventor name: MITCHELL, DALE ROBERT,C/O BIO FOCUS Inventor name: SUGIURA, SATOSHI,C/O TEIJIN PHARMA LIMITED Inventor name: YAMAKOSHI, YUKO,C/O TEIJIN PHARMA LIMITED Inventor name: OUE, YASUHIRO,C/O TEIJIN PHARMA LIMITED Inventor name: FUJINO, AIKO,C/O TEIJIN PHARMA LIMITED Inventor name: UNOKI, GEN,C/O TEIJIN PHARMA LIMITED Inventor name: TAKAKUWA, MIKA,C/O TEIJIN PHARMA LIMITED Inventor name: MAKINO, HIROAKI,C/O TEIJIN PHARMA LIMITED Inventor name: IMAI, MINORU,C/O TEIJIN PHARMA LIMITED Inventor name: KOSUGI, TOMOMI,C/O TEIJIN PHARMA LIMITED Inventor name: SUZUKI, NAOTAKA,C/O TEIJIN PHARMA LIMITED Inventor name: KATAOKA, KENICHIRO,C/O TEIJIN PHARMA LIMITED |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080901 |
|
RTI1 | Title (correction) |
Free format text: PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES |
|
17Q | First examination report despatched |
Effective date: 20100908 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110119 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1084664 Country of ref document: HK |